Peptides for fat loss — what research has explored, by mechanism

That gap — between the simple model and the biological reality of individual metabolism — is where the peptide fat-loss conversation is loudest. It is also where the marketing is most aggressive and the evidence most uneven. Fat loss is the most commercially prominent category in the compounded peptide world, and the distance between what's approved, what's researched, and what's being sold is wider here than in almost any other area. Mapping it honestly, by mechanism rather than by brand, is the goal.

The GLP-1 receptor agonists occupy one end of this landscape, and they're there for a reason: they have the strongest evidence of any peptide-adjacent class for meaningful, sustained fat loss. Semaglutide is a GLP-1 receptor agonist approved by the FDA — first as Ozempic for type 2 diabetes management, then as Wegovy specifically for chronic weight management. GLP-1, glucagon-like peptide-1, is an incretin hormone produced in the gut after eating. It signals satiety to the brain, slows gastric emptying, and influences the hypothalamic circuits that regulate appetite. Semaglutide is a synthetic analog of GLP-1, modified for longer half-life and once-weekly dosing. In the STEP trials, participants using semaglutide lost on average fifteen percent of body weight — a magnitude of fat loss that previously required bariatric surgery. It is the compound in this landscape with the most robust clinical evidence. It is also the one with the most significant regulatory and supply context: the FDA has on multiple occasions placed semaglutide on shortage lists, which opened compounding windows, and those windows have since closed and re-opened in complicated regulatory cycles that your prescribing provider will need to navigate in real time.

Tirzepatide adds a second mechanism: it is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Approved as Mounjaro for type 2 diabetes and Zepbound for weight management, tirzepatide has shown fat-loss outcomes in trials that exceed semaglutide's — roughly twenty percent of body weight on average in the SURMOUNT trials. The GIP receptor contribution appears to work synergistically with GLP-1 signaling in both central appetite suppression and peripheral fat metabolism. Tirzepatide is FDA-approved; compounded versions exist in the same regulatory gray zone as semaglutide.

Retatrutide extends the mechanism further still — it is a triple agonist of GLP-1, GIP, and glucagon receptors. Phase II data showed mean weight loss approaching twenty-five percent. Glucagon receptor activation adds direct stimulation of energy expenditure to the appetite suppression of GLP-1/GIP, creating a fat-mobilization mechanism on top of the intake-reduction mechanism. Retatrutide is not yet FDA-approved; it is in ongoing trials and represents the next generation of the GLP-class.

Setmelanotide is in a different category altogether. It's a melanocortin-4 receptor agonist approved by the FDA specifically for monogenic obesity — the rare genetic forms of severe obesity caused by deficiencies in the POMC, PCSK1, or LEPR genes. It is not a general weight-loss compound and is not appropriate outside of the specific genetic context it was developed for. It appears here because it sits in the appetite-regulation space, but its mechanism and indication are distinct. Using setmelanotide outside its approved genetic indication is not what the evidence supports.

The direct lipolysis category is where the evidence gets substantially thinner. AOD-9604, also known as Fragment 176-191, is a fragment of the growth hormone molecule — specifically the portion believed to have fat-mobilizing properties without the growth-promoting effects of full growth hormone. The research hypothesis was that this fragment could activate beta-3 adrenergic receptors in adipose tissue to stimulate lipolysis. AOD-9604 was actually taken through Phase III trials by Metabolic Pharmaceuticals in Australia for obesity — and failed to show efficacy over placebo in those trials. It was subsequently abandoned as an obesity drug. It has since re-entered the compounded peptide market under various framings, and the compound is widely sold and discussed online. The honest representation is that it had human clinical trial data — and that data did not support its efficacy for fat loss. That's a different position than never having been tested. Lipo-B injections — typically a combination of lipotropic compounds including methionine, inositol, and choline, sometimes with B vitamins — are a different class entirely, more adjunct to metabolic function than a direct lipolytic agent, with no significant clinical evidence for fat loss specifically.

The GH-axis category is more nuanced and more broadly evidenced than direct lipolysis. Growth hormone is genuinely involved in fat metabolism, particularly visceral fat mobilization. GH-releasing peptides work by stimulating the pituitary to produce more endogenous growth hormone rather than replacing it directly. Tesamorelin is the standout here: it is FDA-approved, specifically for the reduction of excess visceral abdominal fat in HIV patients with lipodystrophy, and has documented clinical evidence for visceral fat reduction in that population. It's a GHRH analog with a more sustained action than natural GHRH. Beyond its specific approved indication, it has been researched and used in compounded form for visceral fat in other contexts, though that represents off-label use without the same evidence base.

Sermorelin is another GHRH analog, the earliest to be used clinically, originally approved for growth hormone deficiency in children. In adults it stimulates GH pulses in a pulsatile, physiologic pattern. Ipamorelin is a selective growth hormone secretagogue receptor agonist — it stimulates GH release without significantly raising cortisol or prolactin as older secretagogues did. CJC-1295 is a GHRH analog with a drug affinity complex that extends its half-life. These are often combined in compounding: CJC-1295 with Ipamorelin is a frequently discussed pairing, and the peripheral effects include GH-driven changes in body composition — decreased fat mass, particularly visceral, and modest lean mass increases. These effects are less dramatic than the GLP-1 class for fat loss specifically, but they operate through a different mechanism and may be relevant in contexts where GH axis support is a goal alongside fat loss. None of these combinations are FDA-approved for fat loss; they're compounded.

The insulin sensitivity and metabolic flexibility angle matters because fat storage isn't just about how much you eat — it's significantly about how your cells handle glucose. Insulin resistance drives preferential fat storage, particularly visceral and hepatic. MOTS-c, the mitochondria-derived peptide, has been studied for AMPK activation and insulin sensitization in preclinical models. AICAR, a synthetic compound that mimics AMPK activation, has been called an exercise mimetic for its metabolic effects. Microdose GLP-1 at sub-satiety doses is used in some clinical contexts primarily for insulin sensitization rather than appetite suppression. These approaches are metabolic rather than directly lipolytic, and the evidence for fat loss specifically is indirect.

Adipotide deserves mention and a specific warning. It's a proapoptotic peptide designed to selectively destroy the vasculature feeding white adipose tissue — essentially cutting off the blood supply to fat deposits. In obese rhesus monkeys, it produced dramatic fat loss results. But the safety profile in those animals was concerning: significant kidney toxicity, including tubular necrosis, was observed. Adipotide is described here as an investigational compound with significant safety concerns identified in primate studies. It has not cleared human safety hurdles and is mentioned primarily because it circulates in online discussions of fat-loss peptides, and anyone considering it should understand the preclinical safety signal clearly.

The amylin analog Cagrilintide is in late-stage clinical development in combination with semaglutide (the combination called CagriSema). Amylin is a peptide co-secreted with insulin that contributes to satiety and slows gastric emptying. Adding amylin-receptor agonism to GLP-1 agonism appears to produce additive effects on weight reduction. The combination has shown over twenty percent weight loss in Phase III data, with the CagriSema trials positioning it as a next-generation alternative to tirzepatide. Cagrilintide is not yet FDA-approved.

The lean mass preservation problem runs through this entire landscape. Aggressive fat loss — whether through GLP-1 agents or other mechanisms — reliably produces some loss of lean muscle mass alongside fat. In the STEP trials, roughly forty percent of weight lost was lean mass in some analyses. Resistance training is the primary mitigation strategy; adequate protein intake is essential. Some providers combine GLP-1 agents with GH-axis support peptides partly for this reason — the body composition trade-off of pure appetite suppression is less favorable than a combination approach. The evidence for this strategy is emerging rather than established, but the mechanistic rationale is sound.

The distance between approved and compounded in this category is particularly important to understand. FDA-approved compounds — semaglutide in Wegovy, tirzepatide in Zepbound, tesamorelin for lipodystrophy — have cleared rigorous safety and efficacy trials and carry those trials' data with them. Compounded versions of those same compounds are produced outside that process, often using different salt forms, and operate in a regulatory framework that is actively shifting. Compounds like BPC-157, AOD-9604, MOTS-c in fat-loss contexts, and various GH secretagogues are research-grade or have failed clinical trials — and are being used clinically based on mechanism and preclinical data rather than established human efficacy.

Caloric balance, protein adequacy, and resistance training have more evidence for favorable body composition than anything in this landscape. That sentence should probably come before everything else in this conversation, but it rarely does, because the metabolic situation is often more complicated than it sounds. Fat loss is the most marketed peptide category. The most evidence sits in the GLP-1 family. Protocol selection should match the individual metabolic picture — the hormonal context, the insulin sensitivity, the lean mass to fat mass ratio, the cardiovascular risk profile — and not the marketing surrounding any particular compound.